Want to see GH full AI Analyst Report?
Top Page
Guardant Health
(NASDAQ:GH)
Select Model
Select Model
Rating:60Neutral
Price Target:
$160.00
▲(8.60% Upside)
Action:Reiterated
Date:07/31/26
The score is driven primarily by weak financial quality—high leverage with negative equity and ongoing losses/cash burn—despite improving trends. Offsetting this, the latest earnings call conveyed strong operational momentum with raised revenue guidance, regulatory wins, and accelerating Screening/Oncology adoption. Technically, the stock is in a favorable longer-term uptrend versus key moving averages, while valuation remains challenging due to negative earnings and no dividend support.
Positive Factors
Revenue Growth & Guidance
Sustained high-single to mid-double-digit revenue growth and a raised full-year guide indicate broad commercial adoption across Oncology, Screening and Biopharma. Durable top-line momentum supports scale economies, partner leverage in trials and continued reinvestment to extend market reach over the next 2–6 months.
Negative Factors
High Leverage & Negative Equity
A sizable debt load and negative equity materially constrain financial flexibility. Over the medium term this increases refinancing and covenant risk, limits capacity for opportunistic M&A or aggressive buybacks, and raises dependence on capital markets or partner financing while scaling Screening.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Guidance
Sustained high-single to mid-double-digit revenue growth and a raised full-year guide indicate broad commercial adoption across Oncology, Screening and Biopharma. Durable top-line momentum supports scale economies, partner leverage in trials and continued reinvestment to extend market reach over the next 2–6 months.
Read all positive factors
Guardant Health Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyGuardant Health (GH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.15B
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth42.74%
EPS Growth-4.60%
CountryUS
Employees2,498
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-3.49
Shares Outstanding134,196,170
10 Day Avg. Volume1,760,827
30 Day Avg. Volume2,920,009
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$191.56Price Target Upside30.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-3.18
Revenue Forecast (FY)$1.35B
Guardant Health Business Overview & Revenue Model
Company Description
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and ...
How the Company Makes Money
Guardant Health generates revenue primarily from selling oncology diagnostic tests and related services. Key revenue streams include: (1) Clinical testing revenue: fees paid for performing Guardant’s molecular tests on patient samples (notably liq...
Guardant Health Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational momentum: broad-based, high-double-digit revenue and volume growth, major FDA approvals (Guardant360 Liquid CDx and a higher-throughput Shield workflow), guideline inclusion and a major payer (UnitedHealth) coverage decision for Shield, record Biopharma results, meaningful margin and cost-per-test improvement initiatives, and expanded commercial reach. Offsetting these positives are elevated operating expenses and investments (S&M and CapEx) to scale Screening, a modest adjusted EBITDA loss and increased free cash flow burn, and outstanding reimbursement/pricing uncertainties (ADLT timing, MolDX/Reveal coverage, USPSTF). On balance, the positive commercial, regulatory and margin trends materially outweigh the near-term cost and reimbursement risks, though execution and payer outcomes remain key near-term sensitivities.Positive Updates
Record Quarterly Revenue and Raised Guidance
Q2 revenue of $335 million, up 44% year-over-year; company raised full-year 2026 revenue guidance to $1.34–$1.36 billion (36%–38% growth).
Negative Updates
Adjusted EBITDA Loss and Cash Burn
Adjusted EBITDA loss of $56 million in Q2 (vs $52 million loss a year ago). Q2 free cash flow burn $70 million (vs $66 million prior year). Full-year 2026 free cash flow burn now guided to $195–$205 million ( ~$10 million higher than prior outlook).
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and Raised Guidance
Q2 revenue of $335 million, up 44% year-over-year; company raised full-year 2026 revenue guidance to $1.34–$1.36 billion (36%–38% growth).
Read all positive updates
Company Guidance
Guardant raised full‑year 2026 revenue guidance to $1.34–$1.36 billion (growth of 36%–38%), with non‑GAAP gross margin expected at 64%–65% and non‑GAAP operating expenses of $1.08–$1.10 billion (up 20%–22% vs. 2025); free cash flow burn is now forecast at $195–$205 million (about $10M above prior outlook) while quarter‑end cash and investments stood at ~ $1.2 billion. By segment, the company expects Oncology revenue to grow ~30% with Oncology volume up ~50%, Biopharma & Data to grow in the low double‑digits, and Screening revenue to be $218–$230 million with Shield tests of 270,000–285,000 (Q2 Shield ASP ≈ $800); Shield cost per test is expected to fall roughly 15% by end of 2026 from ~ $410 (with a $200 target by 2028). Management also reiterated that the rest of the business (ex‑Screening) should generate positive free cash flow in 2026, they remain on track for ADLT designation for Guardant360 Liquid CDx in H1 2027 (supporting a longer‑term ASP uplift toward roughly $5,000), and they are targeting company‑wide cash‑flow breakeven by the end of 2027.Guardant Health Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18B | 982.02M | 739.02M | 563.95M | 449.54M | 373.65M |
| Gross Profit | 769.16M | 633.01M | 449.22M | 336.90M | 293.21M | 250.74M |
| EBITDA | -411.19M | -373.91M | -390.12M | -433.31M | -614.91M | -359.62M |
| Net Income | -453.44M | -416.28M | -436.37M | -479.45M | -654.59M | -405.67M |
Balance Sheet | ||||||
| Total Assets | 1.91B | 2.01B | 1.49B | 1.79B | 1.61B | 2.20B |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 1.20B | 839.98M | 1.17B | 1.01B | 932.75M |
| Total Debt | 1.70B | 1.71B | 1.34B | 1.35B | 1.37B | 1.37B |
| Total Liabilities | 2.14B | 2.11B | 1.63B | 1.63B | 1.55B | 1.56B |
| Stockholders Equity | -222.87M | -99.31M | -139.65M | 158.68M | 60.18M | 645.00M |
Cash Flow | ||||||
| Free Cash Flow | -240.72M | -233.07M | -274.94M | -345.46M | -386.92M | -284.05M |
| Operating Cash Flow | -185.19M | -184.76M | -239.86M | -324.98M | -309.46M | -209.02M |
| Investing Cash Flow | -118.53M | -627.20M | -261.31M | 840.25M | 149.82M | -63.16M |
| Financing Cash Flow | 737.80M | 671.13M | -996.00K | 477.38M | -189.09M | -66.82M |
Guardant Health Technical Analysis
Positive
147.33
Price Trends
147.67
Positive
121.03
Positive
110.68
Positive
Market Momentum
4.84
Negative
59.65
Neutral
71.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GH, the sentiment is Positive. The current price of 147.33 is below the 20-day moving average (MA) of 155.51, below the 50-day MA of 147.67, and above the 200-day MA of 110.68, indicating a bullish trend. The MACD of 4.84 indicates Negative momentum. The RSI at 59.65 is Neutral, neither overbought nor oversold. The STOCH value of 71.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GH.
Guardant Health Risk Analysis
Guardant Health disclosed 70 risk factors in its most recent earnings report. Guardant Health reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Guardant Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $8.79B | 22.05 | 11.28% | 6.38% | 2.96% | 9.52% | |
71 Outperform | $12.91B | 56.13 | 3.27% | 0.25% | 4.05% | -10.40% | |
67 Neutral | $6.01B | -288.74 | -1.95% | ― | 18.92% | -37.55% | |
67 Neutral | $45.08B | -232.32 | -11.73% | ― | 37.82% | 28.02% | |
60 Neutral | $22.15B | -47.31 | 211.46% | ― | 42.74% | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GH
Guardant Health
165.11
106.54
181.90%
RVTY
Revvity
117.88
27.20
30.00%
QGEN
Qiagen
43.00
-5.87
-12.01%
RDNT
Radnet
76.95
8.54
12.48%
NTRA
Natera
315.96
158.26
100.36%
Guardant Health Corporate Events
Executive/Board ChangesShareholder Meetings
Guardant Health Shareholders Reject Executive Pay in Annual Vote
Neutral
Jun 18, 2026
At its annual meeting of stockholders held on June 17, 2026, Guardant Health, Inc. saw shareholders re-elect Ian Clark and Manuel Hidalgo Medina to the board of directors and ratify the appointment of Deloitte Touche LLP as its independent regist...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.